Synvista Therapeutics (SYI) Announces FDA Received Its Application for 510(k) Clearance for HAPTOCHEK(TM) Test Kit
More News related to SYI
- Synvista Therapeutics (SYI) Announces Termination of Clinical Trials of Alagebrium and SYI-2074
- Synvista Therapeutics (SYI) Announces FDA Received Its Application for 510(k) Clearance for HAPTOCHEK(TM) Test Kit
- Atticus Capital 13F Shows New Stakes in Chesapeake (CHK), Focus Media (FMCN), Google (GOOG), Peabody (BTU); Lowers Stakes in Freeport-McMoRan (FCX), MasterCard (MA), NYSE Euronext (NYX)
- Summary of Atticus Capital's 13F; New Stakes In Baidu, Nymex and Boeing (BIDU, NMX & BA)
- Barakett's Atticus Capital Shows New Stakes in Cisco (CSCO), Apple (AAPL), Merrill Lynch (MER) and Citigroup (C), Among Others
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Synvista Therapeutics, Inc. (AMEX: SYI) today announced that it has submitted, and that the FDA has received its application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit. The 510(k) submission begins a 90-day review process, during which the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
